Melanoma Trials in Marburg, Germany
Conditions / Melanoma / Marburg, Germany
Melanoma has been the subject of sustained clinical investigation across multiple research sites.
11 total trials for this combination
Showing top 10 of 11 trials
Trials
| NCT ID | Title | Status | Phase |
|---|---|---|---|
| NCT06054555 | A Study to Evaluate ABP 206 Compared With OPDIVO® (Nivolumab) in Subjects With Unresectable or Metastatic Melanoma | ACTIVE_NOT_RECRUITING | PHASE3 |
| NCT02156804 | A Single-Arm, Open-Label, Multicenter Clinical Trial With Nivolumab (BMS-936558) for Subjects With Histologically Confirmed Stage III (Unresectable) or Stage IV Melanoma Progressing Post Prior Treatment Containing an Anti-CTLA4 Monoclonal Antibody (CheckMate 172) | COMPLETED | PHASE2 |
| NCT02967692 | A Study of the Anti-PD1 Antibody PDR001, in Combination With Dabrafenib and Trametinib in Advanced Melanoma | TERMINATED | PHASE3 |
| NCT00796445 | A Phase III Study to Test the Benefit of a New Kind of Anti-cancer Treatment in Patients With Melanoma, After Surgical Removal of Their Tumor | TERMINATED | PHASE3 |
| NCT01682083 | Dabrafenib With Trametinib in the Adjuvant Treatment of High-risk BRAF V600 Mutation-positive Melanoma (COMBI-AD). | COMPLETED | — |
| NCT00518895 | Trial of Dacarbazine With or Without Genasense in Advanced Melanoma | COMPLETED | PHASE3 |
| NCT00942162 | A Study to Test the Benefit of a New Anti-cancer Treatment in Patients With Unresectable Advanced Melanoma | COMPLETED | PHASE2 |
| NCT01584648 | A Study Comparing Trametinib and Dabrafenib Combination Therapy to Dabrafenib Monotherapy in Subjects With BRAF-mutant Melanoma | COMPLETED | PHASE3 |
| NCT05625399 | A Study of Subcutaneous Nivolumab + Relatlimab Fixed-dose Combination (FDC) in Previously Untreated Metastatic or Unresectable Melanoma | ACTIVE_NOT_RECRUITING | PHASE3 |
| NCT02434107 | Complete Lymph Node Dissection vs Watchful Waiting in Patients With Malignant Melanoma (Thickness of 1,0mm+ and Evidence of Metastases in the Sentinel Node) | COMPLETED | NA |